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Letter to the editor 
Autosomal recessive primary microcephaly (MCPH) is a rare and genetic heterogeneous 
neurodevelopmental disorder characterized by a pronounced reduction of brain volume and 
intellectual disability (1, 2). To date, 13 MCPH genes have been identified (reviewed in (3)), 
eight of them in the last five years, showing the rapid progress in this field. Still, families with 
an MCPH phenotype who do not carry mutations in these known MCPH genes exist, 
indicating further genetic heterogeneity. Here, we report the results of a genetic study on a 
cohort of 15 consanguineous families (46 affected individuals) with an MCPH phenotype 
from the Azad Jammu and Kashmir (AJK) territory in Northern Pakistan (Table 1, 
Supplemental Figure 1). All families were examined clinically on field trips with 
microcephaly and intellectual disability detected in all affected individuals (Supplemental 
Table 1), but no other obvious malformations. Applying whole exome sequencing, according 
to methods described previously (4), followed by Sanger sequencing, we identified mutations 
in the four known MCPH genes ASPM (MIM*605481), CENPJ (MIM*609279), MCPH1 
(MIM*607117), and STIL (MIM*181590) in these families. We detected one novel 
homozygous frameshift mutation (c.5606_5607insC, p.H1870Tfs*26) in the ASPM gene 
predicted to result in a truncated protein in one family. Further 12 MCPH families carried 
previously reported homozygous mutations in the ASPM gene: (i) the frameshift mutation 
c.8200_8201delAA (p.N2734Lfs*16) (5) in five families, (ii) the nonsense mutation 
c.2967G>A (p.W989*) (6) in three families, and (iii) the missense mutation c.9539A>C 
(p.Q3180P) (7), the nonsense mutations c.9190C>T (p.R3064*) (6) and c.2938C>T (p.R980*) 
(http://www.ncbi.nlm.nih.gov/clinvar/variation/21569/), and the frameshift mutation 
c.7782_7783delGA (p.K2595Sfs*6) (6), in one family each. Family MC6 carried a novel 
homozygous splice site mutation on chromosome position chr1:197125193T>C (GRCh38.p2 
assembly, NC_000001.11) in addition to the missense mutation c.9539A>C (p.Q3180P). In 
one family the homozygous frameshift mutation c.17delC (p.S7Lfs*4) (8) in the CENPJ gene 
was identified. Family MC4 carried a heterozygous missense mutation in the MCPH1 
(c.2422G>A; p.V808I) as well as in the STIL gene (c.1136C>T in transcript variants 1-4; 
c.995C>T in transcript variants 5 and 6; p.S379F in isoforms 1-3; p.S332F in isoforms 4 and 
5). While homozygosity of these mutations is known to cause MCPH1 and MCPH7, 
respectively, it can only be speculated at this point that a combination of heterozygous 
mutations in two different MCPH genes can potentially result in a MCPH phenotype. 
However, none of these two mutations are predicted to be pathogenic with respect to 
PolyPhen2, SIFT, MutationTaster or CADD. The MCPH1 and the STIL mutation have been 
observed in only 3/120,734 alleles and 291/120,486 alleles, respectively, in ExAc. Further 
functional analysis and analysis of other possible candidate genes will be necessary to identify 
the MCPH-causing mutation in this family. In summary, we have identified both novel and 
known mutations in MCPH genes with the majority of families carrying mutations in the 
ASPM gene. This study implies that the high incidence of MCPH in Northern Pakistan can to 
a large extent be attributed to ASPM mutations, which coincides with a high percentage of 
ASPM mutations in MCPH worldwide.  
Supplemental Figure 1. Identified MCPH gene mutations in relation to Pakistani cohort 
residence, pedigrees and pictures of patients.  
(A) Map of Pakistan with Azad Jammu and Kashmir (AJK) territory marked in red. 
(http://commons.wikimedia.org/wiki/File:Azad_Kashmir_in_Pakistan.svg#/media/File:Azad_
Kashmir_in_Pakistan.svg). (B) MCPH gene mutations identified in families in the AJK 
territory. The two novel mutations identified in the ASPM gene are marked with a red box. 
Known mutations in the ASPM gene are marked with blue boxes. The mutation identified in 
the CENPJ gene is marked with a brown box. (Modified map from 
http://www.hrw.org/reports/2006/pakistan0906/1.htm). (C) Pedigrees of consanguineous 
families and pictures of affected family members. 
 
Supplemental Table 1. Head circumferences (OFC) with standard deviations (SD) of 
patients. 
  
 
Table 1: MCPH gene mutations in cohort of Northern Pakistani descent 
Gene Chromosome position
1
 DNA variation
2
 Exon Protein variation
3
 Family ID Reference
4
 
ASPM g.197125190G>A c.2938C>T 11 p.R980* MC1 ClinVar database
5
 
g.197125161C>T c.2967G>A 11 p.W989* MC2, 3, 12 (6) 
g.197101050_197101051delTT c.8200_8201delAA 18 p.N2734Lfs*16 MC5, 8, 13, 14, 15 (5) 
g.197090947T>G 
c.9539A>C (transcript variant 1) 23 p.Q3180P (isoform 1) 
MC6 (7) 
c.4784A>C (transcript variant 2) 22 p.Q1595P (isoform 2) 
g.197093156G>A 
c.9190C>T (transcript variant 1) 21 p.R3064* (isoform 1) 
MC9 (6) 
c.4435C>T (transcript variant 2) 20 p.R1479* (isoform 2)  
g.197101468_197101469delTC c.7782_7783delGA 18 p.K2595Sfs*6 MC11 (6) 
g.197103644_197103645insG c.5606_5607insC 18 p.H1870Tfs*26 MC16 novel 
g.197125193T>C
6
 - - ? MC6 novel 
CENPJ g.24913009delG c.17delC 2 p.S7Lfs*4 MC7 (8) 
1
Reference sequences: ASPM, NC_000001.11; CENPJ, NC_000013.11 
2
Reference sequences: ASPM, NM_018136.4 (transcript variant 1), NM_001206846.1 (transcript variant 2); CENPJ, NM_018451.4 
3
Reference sequences: ASPM, NP_060606.3 (isoform 1), NP_001193775.1 (isoform 2); CENPJ, NP_060921.3 
4
First publication of the mutation 
5
http://www.ncbi.nlm.nih.gov/clinvar/variation/21569/ 
6
Splice site mutation in intron 10  
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Whole exome sequencing and bioinformatic methods. Afflicted patients 
from all families were subjected to exome sequencing. Genomic DNA was 
isolated from blood samples using standard methods. Three micrograms of 
genomic DNA were enriched using the Agilent Human All Exon V4 kit (Agilent 
Technologies, Santa Clara, CA, USA) following the manufacturer's protocol. 
Whole-exome libraries were sequenced on an Illumina HiSeq 2000 system for 
2x101 cycles following the manufacturer's instructions (Illumina, San Diego, 
CA, USA). In total, we obtained 78-119 million paired-end 101 bp reads per 
sample, of which 97.54-99.8% could be mapped onto the human genome. 
After removing duplicated reads, which were possibly derived from PCR 
artifacts, 72-108 million unique reads were mapped to the targeted protein 
coding regions, resulting in an average of 99-150 fold-coverage within the 
targeted coding region. Using the GATK 3.2.2, we detected 27,376-28,950 
SNPs and INDELs in the exome of each family member, of which 98.3-98.4% 
were known variants deposited in dbSNP 135. Given the cohort, we searched 
for recessive inheritance patterns. All raw sequencing reads were mapped 
onto UCSC hg19 using BWA mem 0.7.10, mappings were converted into 
BAM file format using samtools 0.1.19. Initial mappings were post-processed 
using GATK following their 'best practices'. In brief, likely PCR duplicates were 
detected using Picard 1.92. Reads were then realigned around sites of known 
INDELs. Finally, raw base quality scores were empirically recalibrated. Single 
Nucleotide Polymorphisms (SNPs) and INDELs were identified using the 
HaplotypeCaller from GATK. Variants were classified as novel or known 
variants according to Single Nucleotide Polymorphism Database dbSNP 135. 
Functional consequences of each variant were annotated using genetic 
variant annotation and effect prediction toolbox snpEff 3.0 for UCSC hg19 
RefSeq genes and ENSEMBL 75 human gene models. The potential 
deleterious effect was evaluated using PolyPhen 2 (Polymorphism 
Phenotyping v2), SIFT (Scale-invariant feature transform), PhyloP, 
MutationTaster, GERP++ (Genomic Evolutionary Rate Profiling), LRT 
(Likelihood Ratio Test), and OMIM (Online Mendelian Inheritance in Man), if 
available. Variants within the cohort were filtered for a recessive inheritance 
pattern. 
Family Pedigree 
ID 
Age of 
exam [y] 
Intellectual 
disability 
OFC 
[cm] 
SD 
MC1 III:1 28 -/(+) 43 -9,48 
 III:2 21 + 37 -13,93 
MC2 III:1 38 ++ 41 -9,40 
 III:9 16 ++ 38 -14,50 
 IV:2 6 - 36 -10,33 
MC3 IV:1 7 + 41 -7,33 
 IV:6 13 + 48 -3,79 
 IV:8 3 - 33 -15,45 
MC4 III:3 27 - 49 -5,04 
MC5 III:1 35 + 49,5 -3,73 
 III:3 30 + 48,26 -5,59 
 IV:1 10 + 40,6 -11,26 
MC6 IV:5 18 ++ 43,18 -9,35 
 IV:6 14 ++ 41,91 -9,76 
 IV:7 20 ++ 40,64 -9,64 
MC7 IV:1 15 + 43,18 -7,88 
 IV:2 20 ++ 43,18 -9,35 
 IV:3 18 ++ 45,7 -7,48 
MC8 IV:2 16 - 49,53 -4,89 
 IV:4 10 + 41,91 -6,96 
 IV:5 13 ++ 45,97 -5,24 
MC9 IV:2 15 + 40,64 -9,57 
 IV:3 16 ++ 41,91 -11,24 
 IV:4 14 ++ 41,4 -8,93 
MC11 V:2 14 + 47,24 -5,66 
 V:3 15 + 45,72 -6,28 
 V:4 16 + 47,49 -5,47 
MC13 IV:1 4 + 40,64 -6,39 
 IV:2 3 + 43,18 -4,01 
 IV:3 8 ++ 43,18 -5,88 
MC14 II:1 50 + 40,64 -11,23 
 III:1 10 -/(+) 45,72 -4,70 
 III:3 12 -/(+) 48,26 -3,09 
 III:4 25 -/(+) 49,53 -4,64 
 III:5 30 -/(+) 45,72 -7,47 
MC15 IV:5 16 -/(+) 40,64 -10,74 
 IV:6 10 ++ 45,72 -4,70 
MC16 IV:1 7 -/(+) 45,72 -3,59 
 IV:2 11 + 42,62 -6,45 
 IV:4 2 + 38,1 -7,23 
 
- =  no; (+) = very mild; + = mild, ++ = severe 
 Referenz Nellhaus, G., Pediatrics, 1968: 
Male, 18 J, OFC Mean = ca. 55,8 cm; - 2 SD = ca. - 2,7 cm  
Male, 16 J., OFC Mean = 55,4 cm; - 2 SD = ca. – 2,4 cm  
Male, 15 J., OFC Mean = 55,0 cm; - 2 SD = ca. – 3 cm  
Male, 14 J., OFC Mean = 54,6cm; - 2 SD = ca. – 2,6 cm  
Male, 10 J., OFC Mean = 53 cm; - 2 SD = ca. – 3,1 cm  
Male, 8 J., OFC Mean = 52,3cm; - 2 SD = ca. – 3,1 cm  
Male, 7 J., OFC Mean = 52 cm; - 2 SD = ca. - 3 cm   
Male, 6 J., OFC Mean = 51,5 cm; - 2 SD = ca. - 3 cm   
Male, 3 J., OFC Mean = 50 cm; - 2 SD = ca. – 2,2 cm   
Male, 2 J., OFC Mean = 49,3 cm; - 2 SD = ca. – 3,1 cm   
 
Female, 18 J, OFC Mean = ca. 55,1 cm; - 2 SD = ca. – 3 cm 
Female, 16 J, OFC Mean = ca. 54,6 cm; - 2 SD = ca. – 2,6 cm 
Female, 15 J, OFC Mean = ca. 54,2 cm; - 2 SD = ca. – 2,7 cm 
Female, 14 J, OFC Mean = ca. 53,9 cm; - 2 SD = ca. – 2,8 cm 
Female, 13 J, OFC Mean = ca. 53,3 cm; - 2 SD = ca. – 2,8 cm 
Female, 12 J, OFC Mean = ca. 52,9 cm; - 2 SD = ca. – 3 cm 
Female, 11 J, OFC Mean = ca. 52,3 cm; - 2 SD = ca. – 3 cm 
Female, 10 J, OFC Mean = ca. 52 cm; - 2 SD = ca. – 2,9 cm 
Female, 7 J, OFC Mean = ca. 51,1 cm; - 2 SD = ca. – 3 cm 
Female, 4 J, OFC Mean = ca. 49,9 cm; - 2 SD = ca. – 2,9 cm 
Female, 3 J, OFC Mean = ca. 49 cm; - 2 SD = ca. – 2,9 cm 
 
 
 
 
